The company is subject to a public tender offer by Omron Healthcare Co., Ltd. for the company's shares and stock acquisition rights, announced on February 10, 2026. The company has recorded 124 million yen in advisory and legal fees related to the tender offer as special losses in Q3 FY2026, with total expected costs of approximately 270 million yen upon completion of the process.
¥270M
›
Summary
The company is subject to a public tender offer by Omron Healthcare Co., Ltd. for the company's shares and stock acquisition rights, announced on February 10, 2026. The company has recorded 124 million yen in advisory and legal fees related to the tender offer as special losses in Q3 FY2026, with total expected costs of approximately 270 million yen upon completion of the process.